Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

The US Food and Drug Administration (FDA) has accepted a resubmission of the supplemental Biologics License Application for ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long ...

Novartis’ immunoglobulin E inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many years, but the company says it has gone one better with new ...

Trump’s pick to lead the Department of Health and Human Services, has for years called attention to what he considers an “epidemic” of chronic disease that has left America’s children ...

Ligelizumab is a next-generation monoclonal anti-immunoglobulin E (IgE) antibody that shows promise for treating chronic hives that arise spontaneously. Sporadic hives that occur often, last anywhere ...

for the treatment of chronic spontaneous urticaria (CSU) in adults and pediatric patients aged 12 years and older inadequately controlled with H1 antihistamine treatment. The original sBLA was ...

Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product ...

A person can look “young and healthy” and still be fighting a battle that leaves them in constant pain, a Belleville resident ...

A child with a new medical diagnosis starts to think of themselves as “different,” as having a limitation. The most common mental health issues they face are anxiety and depression. Chronic medical ...